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The t(8;21) abnormality occurs in a minority of acute myeloid leukemia (AML) patients. The translocation results in an in-frame
fusion of two genes, resulting in a fusion protein of one N-terminal domain from the AML1 gene and four C-terminal domains
from the ETO gene. This protein has multiple eﬀects on the regulation of the proliferation, the diﬀerentiation, and the viability
of leukemic cells. The translocation can be detected as the only genetic abnormality or as part of more complex abnormalities. If
t(8;21) is detected in a patient with bone marrow pathology, the diagnosis AML can be made based on this abnormality alone.
t(8;21)is usuallyassociatedwitha good prognosis.Whetherthe detection ofthefusiongenecanbe used forevaluationofminimal
residual disease and risk of leukemia relapse remains to be clariﬁed. To conclude, detection of t(8;21) is essential for optimal
handling of these patients as it has both diagnostic, prognostic, and therapeutic implications.
1.Introduction
Acute myeloid leukemia (AML) is a heterogeneous bone
marrow malignancy, and patients with the cytogenetic
t(8;21) abnormality represent a subset with speciﬁc clinical
and biological characteristics [1]. The translocation fuses
the AML1 gene (also called RUNX1) on chromosome 21
with the ETO gene (also referred to as the RUNX1T1 gene
that encodes the CBFA2T1 protein) on chromosome 8. The
criteria for the diagnosis diﬀers from other AML patients;
the leukemia cells show biological characteristics that are
uncommon in other AML subsets, and the prognosis after
intensive chemotherapy is better for these patients than
for the majority of AML patients [1]. t(8;21) was the ﬁrst
cytogenetic abnormality discovered in AML [2], and today
it oﬀers a unique example of how a cytogenetic abnormality
is used to deﬁne a distinct subgroup of patients. The AML1
gene has p.d.d. been reported to be involved in 39 diﬀerent
rearrangements and most of them have been detected in
myeloid malignancies. In the present paper we describe
the biology and clinical characteristics of the most common
t(8;21) abnormality.
2.The t(8;21)AbnormalityinHuman AML
2.1. Frequency and Predisposition. The t(8;21) abnormality
is found in approximately 5%–10% of all AML cases and
10%–22% of AML cases with maturation corresponding to
the previous FAB class M2 [3–8]. The incidence of AML
with favourablecytogeneticabnormalities decreaseswith age
[9, 10]; this is also true for t(8;21) that is most common in
children/younger patients [11]a n du n c o m m o ni np a t i e n t s
above 60 years of age [10]. Approximately 10%–20% of
children with AML have this translocation [12–15]. The
detection of t(8;21) transcripts in Guthrie cards suggests
that the initiating events can occur in utero [16]. This is
also supported by studies of umbilical cord leukocytes that
have described an association between prenatal pesticide
exposure (i.e., detection of pesticides in meconium) and
the detection of t(8;21) in the leukocytes and the level of2 Journal of Biomedicine and Biotechnology
the fusion transcript then correlated with the pesticide level
[17].
Tissue-speciﬁc genomic organization probably con-
tributes to the formation of this disease-speciﬁc transloca-
tion. Studies of the nuclear architecture have concluded that
chromosomes 8 and 21 tend to colocalize in myeloid cells
[18]. Furthermore, the chromatin organization at intron 5 of
the RUNX1/AML1 gene, where the sequenced breakpoints
have been mapped, are characterized by reduced histone
H1 levels and increased levels of hyperacetylated H3 for
AML1 expressing cells. Induction of DNA damage can then
induce formation of t(8;21) in the HL-60 AML cell line but
not in nonhematopoietic HeLa cells [19]. Thus, both the
nuclear microarchitecture and epigenetic mechanisms seem
to be important for the risk of t(8;21) formation in myeloid
cells. The AML1-ETO fusion protein alone is not suﬃcient
for leukemia development (see Section 9), but the protein
downregulates the expression of DNA repair enzyme 8-
oxoguanine DNA glycosylase (OGG1), which may then lead
toadditionalgeneticabnormalitiesrequiredfordevelopment
of AML [20].
2.2. AML1-ETO: Variant Rearrangements and Combination
with Other Genetic Abnormalities. The t(8;21) generates
two fusion genes, AML1-ETO and ETO-AML1, but only
the AML1-ETO transcript transcribed from the deriva-
tive 8 chromosome is detectable by reverse transcriptase
polymerase chain reaction (RT-PCR). Simple reciprocal
translocation is by far the most common abnormality
for creating AML1-ETO fusions, but the fusion can also
occurs through variant rearrangements (Figures 1(a), 2(a)).
The translocation can involve several chromosomes and
occur together with inversion of the derivative 8 chro-
mosome (e.g., inv(8)(p21;q22)t(8;21), inv(8)(q22q24)) [21,
22]. AML1-ETO fusion can also be a result of insertion,
and both ins(21;8) and ins(8;21) have been described [23]
(Figure 2(b)). These variant rearrangements can be cryptic
and easily overlooked by conventional G-banding, and their
frequencies are therefore unknown.
The t(8;21) abnormality is often detected together with
additional cytogenetic or molecular genetic abnormalities; a
majority of the patients seem to have additional abnormal-
ities (Table 1)[ 3]. These abnormalities are often numerical,
but other translocations or deletions can also be detected.
Chromosome 9 Alternations. Deletion of chromosome 9q,
the del(9q) abnormality, is recurrent but uncommon in
AML, and it was detected only in 81 out of more than 5000
patients that entered 3 MRC studies [26]. The deletion was
then detected in combination with t(8;21)for 29 out of these
81 patients, and the karyotyping indicated that a common
area of deletion in region 9q21-22 was present in more than
90% of the cases. Targeted analysis against AML1-ETO was
not performed in this study. del(9q) has also been found
cooccurring with fusion due to insertion [44]. Based on the
results from several clinical studies, the del(9q) abnormality
seems to be present in 15%–35% of AML patients with
t(8;21) [24, 26]. There was no indication from the MRC
data for an adverse prognostic impact of this additional
abnormality; patients with t(8;21) together with del(9q) had
a 5-year overall survival of 75% in this study [26].
Sweetser et al. investigated the molecular genetics of
43 patients with del(9q) [45]. They described a commonly
deleted region of 2.4 Mb containing 11 genes, 7 of these
beingdownregulated indel(9q)AMLcompared withnormal
CD34+ hematopoietic cells or AML cells with normal
karyotype. Two of these genes, TLE1 and TLE4, are most
likely tumor suppressor since, loss of expression in AML1-
ETO expressing cells leads to increased proliferation and cell
survival.
Numerical Abnormalities. Loss of sex chromosomes is espe-
cially commonint(8;21)AMLpatients(Table 1).Lossofone
Xchromosomedoesnotseemtohaveanyprognosticimpact,
whereas a recent study described a weak good prognostic
impact for -Y [7].
Other Cytogenetic Abnormalities. Several abnormalities have
been described in patients with t(8;21) AML such as trisomy
4 and 8, but these combinations are uncommon, and their
possible prognostic impact remains to be investigated. Other
abnormalities include tetraploid or near-tetraploid clones
[46].
Mutations of KIT. Wang et al. characterized c-kit mutations
in a group of 54 AML patients with t(8;21), and they
observed mutations for 26 of these patients (Figure 3)[ 30].
(i) 21 patients had abnormalities in the tyrosine kinase
domain, four patients had mutations in the jux-
tamembrane or extracellular domains, and the last
patient had a mutation in the kinase insert sequence
between the adenosine triphosphate binding and
phosphotransferase regions of the tyrosine kinase
domain.
(ii) Seven diﬀerent point mutations, three internal tan-
demduplications(ITD),andoneaminoaciddeletion
were detected.
(iii) The most common KIT abnormality was the N822K
mutation (10/26) followed by three variants of D816
mutations (9/26); this is similar to another study
[31].
Thus, many diﬀerent KIT mutations have been detected
in combination with t(8;21), but mutations in the tyrosine
kinase domain predominate [30–32]. The incidence of KIT
mutations in t(8;21) AML varies between 6%–31% in
most clinical studies [30–41], and one exceptional study in
children reported an incidence of 43% [47].
The biological impact of diﬀerent KIT mutations was
investigated in a recent experimental study [48]. These
authors compared the eﬀects of coexpressing either (i) the
more common KITD 814V mutation within the tyrosine
kinase domain or (ii) the less common deletion within Exon
8 (E8D419) with AML1-ETO in an experimental animal
model. Their observations suggested that the KIT mutations
w e r ei m p o r t a n tf o rt h ed i s e a s ep h e n o t y p ea n dt h eK I T
deletion was associated with a less aggressive disease.Journal of Biomedicine and Biotechnology 3
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Figure1:Domainorganizationofthefull-length andalternativeAML1-ETO fusionproteins.(a)Thefull-length AML1-ETO(A1-E)protein
is shown, where most of the ETO (RUNX1T1) gene is fused into the N-terminal 177aa of AML1 (RUNX1) gene giving rise to a transcript
coding for a protein of 752 amino acids (aa). The AML1 gene encodes the Runt homology domain (RHD) which is a DNA-binding protein,
while ETO encodes four highly conserved functional domains called nervy homology domains (NHR1-4). (b) Diﬀerent fusion transcripts
arisedue to alternative exon usageand splicing, which give rise to truncated proteins lackingNHR domains.Protein size (i.e., number ofaa)
is shown on the right with the number of additional aa that were not included in the original sequence. These alternative A1-E transcripts
can be coexpressed alongside the full-length transcript and have diﬀerent leukemogenic capabilities.
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Figure 2: Cytogenetic analysis of AML blasts by G-banding and FISH. (a) The derivative chromosomes from a simple reciprocal
translocation between 8q22 and 21q22 are detectable by G-banding (upper panel) and the translocation can be veriﬁed using FISH probes
(lower panel) against ETO and AML1. With this particular probe (Vysis LSI ETV6(TEL)/RUNX1(AML1) ES Dual Color) fusion signals will
appearbothonderivative 8andderivative 22.(b) Inrarecases,AML1-ETOfusionoccurs asaresultofinsertion.Smallinsertionscanonlybe
detected usingFISH probes. In this case,thetranslocationt(7;8)(q11;q22)between chromosome7and 8andthe 9q deletion del(9)(q12q22)
were detected. As deletion 9q is rare in AML and can coexist with AML1-ETO fusion, FISH analysis was, therefore, performed. Only one
fusion signal on derivative 22 was detected, indicating an ins(21;8)(q22;q22q22) insertion. (c) AML1 can also be involved in translocations
with other partners mimicking complex t(8;21). In this case, there is a translocation between 9q22 and 21q22. FISH analysis using in-house
split-signal probes against AML1 veriﬁed the involvement of these genes, whereas the gene on derivative 9 is unknown.4 Journal of Biomedicine and Biotechnology
Table 1: Genetic abnormalities commonlydetected in combination with t(8;21).
Abnormality Frequency in t(8;21) AML Documented prognostic impact Reference
Chromosomalabnormalities
-X in female patients 30%–40% None [7, 24, 25]
-Y in male patients 50%–60% Possible improved [7, 24, 25]
Del(9q) 15%–35%; most studies
state 15%–20% None [7, 24–26]
Trisomy 8 8% [27]
Complex abnormalities 9%–23% Adverse prognosis [27–29]
Molecular abnormalities
KIT mutations 25%–50% Possible adverse prognosis [30–41]
JAK2V617F 6%–8% [36, 42]
Flt3 -ITD 5% Adverse prognosis [24, 33, 43]
Flt3 D853 3%–7% [24, 43]
Extracellular domains Intracellular domains
Exon 8 Exon 11 Exon 17
TM
N Ig-like domains JMD TK1 KIS TK2 C
502(AYFNF) repeat
D419 del
I571 +14
Q575 +17
I748T D816Y, D816V
D816H, N822K
V825I, L773S
Figure 3: General architecture of the c-kit receptor and the mutations described in combination with the t(8;21) abnormality in the
study by Wang et al. [30]. The c-kit type III receptor tyrosine kinase consists of an extracellular ligand-binding portion comprising ﬁve
immunoglobulin-(Ig-) like repeats, a single transmembrane (TM) domain, a juxtamembrane domain (JMD), and a cytoplasmic portion
containing and a split tyrosine kinase domain (TK1 and TK2) with a kinase insert sequence (KIS). Locations of c-kit abnormalities found
in t(8;21) AML are indicated by the arrows. c-kit mutations are found more frequently within the extracellular ﬁfth immunoglobulin-like
domain(exon 8) and the second tyrosine kinase domainwhich contains the activation loop (exon 17).
The possible prognostic impact of KIT mutations has
been investigated in several relatively small studies including
33–54 patients [30, 32, 34, 36] that all have described an
adverse impact on relapse rate and/or long-term survival.
Relapse rates as high as 70%–80% have been observed
[31, 33, 34]. An adverse impact on overall survival was
also described in the study reported by Boissel et al. that
included 56 patients [33]. However, several recent studies
have described no prognostic impact of the KIT mutations
in t(8;21) AML both for adult patients [35, 38, 39]a n di n
children AML [40, 47].
Flt3-Abnormalities. Flt3-ITD occurs at a relatively low fre-
quency in t(8;21) AML and seems to have an adverse
prognostic impact also in these patients (Table 1)[ 33].
Animal models suggest that both AML1-ETO and Flt3-ITD
alone are insuﬃcient to cause leukemogenesis, but they may
cooperate in inducing AML [49]. Flt3 mutations seem to
be associated with an adverse prognosis in patients with
t(8;21);a recentpreliminary reportdescribeda 3-yearoverall
survival of only 26% [35].
JAK2V617F Mutations. Only three studies have investigated
these mutations in t(8;21) AML, and they occurred in less
than 10% of the patients [35, 36, 42].
Ras Mutations. Mutations in NRas and KRas appear to be
more frequent in pediatric than in adult patients, but they
do not seem to have any prognostic impact in either group
[11, 33, 35, 38]. Even though Ras mutations, thus, do not
seem to have any impact on chemosensitivity, experimental
studies suggest that these mutations are important in leuke-
mogenesis and promote progression towards transformation
in cells expressing the t(8;21) fusion protein [50].
PDGF Receptor Mutations. Results from animal models
suggest that PDGF-receptor (PDGFR) mutations may coop-
erate with AML1-ETO in leukemogenesis (see below),
and PDGFRA seems to be frequently expressed in t(8;21)
AML cells at least for pediatric patients [51]. However,
PDGFRA mutations seem to be very uncommon in these
patients although a N870S mutation has been described
in the homologous domain of the activating KIT and Flt3
mutations.Journal of Biomedicine and Biotechnology 5
Other Molecular-Genetic Abnormalities. Mutations in AML1
and in the hematopoietic transcription factor PU-1 have
been described in exceptional patients with t(8;21) AML
[25]. The t(8;21) abnormality does not seem to coexist with
CEBPA mutations [52], or any of the recently described
mutations in IDH 1/2 [53, 54] or DNMT3A [54].
2.3. t(8;21) in Secondary AML. Approximately 10%–20% of
all cases of t(8;21) AML are secondary [25, 27]a n dc a nb e
detected after treatment for hematologic malignancies (e.g.,
T-ALL,Hodgkin’sdisease,andnon-Hodgkin’slymphoma)as
well as solid tumors (e.g., breast, lung, prostate, esophageal,
and thyroid cancer) [55–57]. Secondary AML seems most
common after chemotherapy, but it has also been described
after radiotherapy alone [55]. The median latency until
diagnosis was 37 months in one study, varying from 11 to
126 months [55].
The secondary form is associated with signiﬁcantly
higher age (median 59 versus 41years) and higher peripheral
blood blast counts than the de novo variant [55]. Secondary
forms are also of the M2-subtype according to the FAB
classiﬁcation,Auerrodsaredetectedonlyforcertainpatients,
and the immunophenotype is similar to de novo forms
usually being CD33+CD34+CD117+CD19+CD56+ [55]. A
recent study described loss of the Y-chromosome in only
12% of all secondary cases compared with 36% of the
de novo t(8;21) subset, whereas the frequencies of other
abnormalities were similar for secondary and de novo forms
[25]. The overall survival of patients with secondary t(8;21)
seems to be signiﬁcantly inferior to patients with de novo
t(8;21) AML [55]. However, even though secondary t(8;21)
AML has a reduced frequency of -Y, this decreased frequency
of a favorable marker cannot explain the adverse prognosis
of secondary t(8;21) AML, because the prognostic impact of
-Y in the de novo group is relatively weak [7].
3.MolecularGeneticsoft(8;21)
3.1. The AML1-ETO Fusion Gene. As described above
(Section 2.2, Figure 2), simple reciprocal translocation is the
most common abnormality. The fusion gene can also be
formed through complex genetic abnormalities that can be
detectedbycytogeneticanalysis, buttheseabnormalities may
also be cryptic and easily overlooked by conventional G-
banding.
T h ei n - f r a m ef u s i o no fA M L 1( R U N X 1 )t oE T O
(RUNX1T1) generally occurs with break-point in AML1 in
intron 5-6andin ETOin intron 1b-2[24,58].The molecular
eﬀects on the fusion protein are given by its structure as
illustrated in Figure 1(a) and Table 2.A M L 1i sat r a n s c r i p -
tion factor that is crucial for hematopoietic diﬀerentiation,
and bindsto enhancers and promoters through itsaminoter-
minal Runt domain; this domain is also present in the
AML1-ETO fusion-protein and the protein can, therefore,
bind to AML1 target gene promoters. However, even though
the fusion protein has binding similarities with AML1, it
causes an altered transcriptional activation and has another
subnuclear localization than the normal AML1 transcription
factor [59]. The ETO/RUNX1T1-encoded protein referred
to as CBFA2T is also a nuclear protein and functions
as a transcriptional repressor through its binding to both
histone deacetylases and transcription factors [60, 61]. The
full-length fusion protein contains all except the 31 N-
terminal amino acids. The NHR-2 domain is important for
homodimerization and interactions with components of the
repressor complexes and seems to be responsible for the
reduced intranuclear mobility of the fusion protein [62–
64]. Thus, the ﬁnal result of this combination will often
be binding to AML1 target gene promoters resulting in
suppression [63]. In addition, the fusion protein is directed
to nuclear microenvironments distinct from those where the
AML1 molecule resides and for this reason may not bind to
all AML1 targets [18, 19]. the fusion protein also colocalizes
with core-binding factor β (CBFβ) within the nucleus; this
colocalization results in a reduced intranuclear mobility of
CBFβ that probably disturbs myeloid diﬀerentiation [64].
3.2. AML1-ETO Has Several Splice Variants. Several splice
variants oftheAML1-ETOgenearepresentint(8;21)patient
cells, and these are all variants in the ETO part of the
molecule [65]. It is generally agreed that the full-length
variant alone does not have a leukemogenic eﬀect; this
conclusion is based on studies using cell lines as well as in
animal models (see Section 6). However, analyses of primary
AML cellswitht(8;21)havedemonstrated thatnumerous in-
frame and out-of-frame transcript variants exist, and these
variants seem to result from alternative splicing, internal
deletions, or breakpoint region insertions [65]. The full-
length molecule encodes a protein of 752 amino acids,
whereas the variants are generally shorter (Figure 1(b)).
(i) The AML1-ETO9a variant includes the alternative
ETO9a exon and results in a truncated molecule of
575 amino acids that lacks the NHR3 and NHR4
domains [66, 67]. In contrast to the full-length
variant, this molecule alone is leukemogenic in a
mouse model [66, 67], but this does not seem to
be true for an alternative model [68]. A possible
explanation for this diﬀerence could be that the
levelsoftranscript/fusion protein seemto be lowerin
thenonleukemicmodel.TheAML1-deriveddomains
together with the ETO-derived NHR-2 domain seem
to be critical for this leukemogenic activity. Coex-
pression of the full-length molecule together with
the AML1-ETO9a variant results in earlier onset of
leukemia and blockade of myeloid diﬀerentiation at
anearlierstage.Thus,thevarioussplicevariantsseem
to cooperate in leukemogenesis.
(ii) Another variant contains an alternative exon at
the C-terminal end instead of NH4R/Mynd; this
exon encodes 27 amino acids in-frame. The variant
is expressed in primary human t(8;21) AML cells
and the encoded protein seems to reduce repressor
activity and tends to form multimeres [69].
(iii) ETO-exon 6a can also be incorporated, potentially
giving rise to two diﬀerent truncated transcripts pre-
dictedtoencodeproteinsof223and395amino acids,
respectively [70]. The shorter variant lacks all four6 Journal of Biomedicine and Biotechnology
Table 2: Molecular structure of the t(8;21) fusion protein, the origin of various domains, and the localization of important molecular
interactions.
Origin Domain (alternative nomenclature) Molecular interactions
N-terminal
AML1 Runt
DNA binding
Binding to CBFβ with formation of heterodimers
Binding of other transcriptional regulators
RUNX1T1-derived domains
NHR1 (eTAFH) Interactswiththenuclearhormonereceptor corepressor
Interaction with the activation domain of E-proteins
(E2A and HEB)
NHR2 (HHR)
Mediates oligomerization with itself or other ETO
molecules
Interacts with the corepressors Sin3, Gﬁ1, and histone
deacetylases 1 and 3
NHR3 (Nervy)
Interacts with the regulatory subunit of type II cAMP-
dependent protein kinase
This domain together with the NHR4 domain is absent
in the leukemogenic AE9a splice variant that naturally
occurs in primary human AML cells with t(8;21)
NHR4 (MYND)
N-CoR and the silencing mediator of retinoid and
thyroid hormone receptor (SMRT); these are associated
with HDACs
SON, an RNA/DNA-binding protein
This domain is absent in the leukemogenic AE9a splice
variant
C-Terminal
NHR domains whereas the longer variant (referred
to as AML1-ETO6a) retains the NHR-1 domain. The
AML1-ETO6a variant alone is not leukemogenic in
animal models but seems to modulate the activity of
the full-length fusion protein.
(iv) The two variants A1bETO and A1cETO were identi-
ﬁedinprimary humanAMLcellsandhaveadditional
sequences upstream to the ﬁrst AML1 exon. Several
in-frame variants ofthese forms havebeenidentiﬁed,
and their ﬁnal eﬀects on the expression of AML1
responsive genes seem to vary from repressive to
activating [65].
To summarize, several molecular variants of the AML1-
ETO fusion protein exist, and the ﬁnal eﬀect of this
chromosomal translocation thus depends on the balance
between these various isoforms.
3.3. The Fusion Protein Has Several Binding Partners. The
AML1/ETO fusion molecule has several partner molecules
[60, 71–78]; nine important partners are listed in the upper
part ofTable 3.Sevenofthese partner moleculesare involved
in the regulation of gene transcription; the molecular
mechanisms behind these eﬀects vary between the partners,
but involve (i) altered histone deacetylation, for example,
regulation of histone acetylation through recruitment of
histone deacetylases or the E-protein interaction with the
histone acetyltransferase; and (ii) altered DNA methylation
through interaction with DNA methyltransferase. Several of
these partner molecules are expected to increase viability,
and proliferation and/or decrease diﬀerentiation, but their
relativecontributiontoleukemogenesisseemstovaryandfor
example theE-proteininteraction seems tobe less important
[79]. The last two partner molecules mentioned in Table 3
include SON that shows a cytoplasmic localization and is
also involved in regulation of proliferation and apoptosis,
and protein kinase A (PKA) that based on the initial study
doesnotseemtohaveanymajorrolein leukemogenesis[78].
Finally, the biological functions and thereby the leukemic
activity of the fusion protein can probably be modulated
through two mechanisms as described in the lower part of
Table 3, either through proteolytic cleavage by calpains or
through alternative splicing.
Even though many biological eﬀects of the fusion
molecule seem to depend on altered expression of AML1-
regulated genes [62–64], other mechanisms involving the
ETO portion of the fusion protein may also be important.
For example, ETO2(MTG16) has corepressor activity and
binds to the transcriptional repressor N-CoR; this binding is
inhibited by the fusion protein probably through occupation
of the ETO2 binding site by the Mynd/NHR4 domain [80].
This eﬀect seems to be important for the myeloid diﬀer-
entiation block. Another example is the oligomerization
domain of ETO that is important for the AML1/ETO-
mediated regulation of cell-cycle progression and apoptosis
[81].Journal of Biomedicine and Biotechnology 7
Table 3: Important proteins that directly interact with or modulate the t(8;21) fusion protein.
Molecule Function of
the molecule Structure: mechanism of interaction Function/biological eﬀect
Molecular interaction with the fusion molecule as a partner molecules
GFI1 [71] Transcription
repressor
GF35N and GF36S variant alleles have repressor
activity. The fusion protein colocalizes and
interacts with the more common GFI136S, and its
repressor activity is thereby inhibited; the fusion
protein does not colocalize or inhibit the
GFI135N repressor activity
GFI1 is a regulator of myeloid diﬀerentiation, and
the interaction and eﬀect of the fusion protein
vary between patients and depend on genetic
diﬀerences
CBPβ [72] Transcription
repressor
Forms heterodimers with the t(8;21) fusion
protein through binding to the Runt domain
from AML1/RUNX1
Animal models suggest that CBPβ is important
for contribution to the fusion proteins inhibition
of neutrophil diﬀerentiation, is essential for its
growth-enhancing eﬀect and cooperation with
receptor-initiated signaling
E-proteins [60] Transcription
factor
DNA-bound E-proteins interact with the histone
acetyl transferase p300/CREB binding protein,
leading to histone acetylation and initiation of
transcription. This eﬀect is silenced by the fusion
protein through (i) preventing E-protein/p300
activation and (ii) local recruitment of HDACs
E-proteins are important regulators of growth,
diﬀerentiation and apoptosis and these functions
are probably inhibited through a stable binding to
the NHR4 domainof the fusion protein
SMRT/N-CoR
complex [73]
Transcriptional
regulators
Binding of the complex together with their
associated HDACs to AML1 target genes through
the fusion protein causes aberrant repression of
transcription
Contributes to the diﬀerentiation block and atten-
uates the eﬀect of the fusion protein on cell
proliferation
UBF1 [74] Transcription
factor
UBF1 binds ribosomal DNA and regulates RNA
polymerase 1 activity (see below); the fusion
protein associates with UBF1
Modulation of RNA polymerase 1-mediated ribo-
somalRNA transcription during interphase
SON [75] Growth
regulation
Binding to the NHR4 domain and is possibly
involved in the antiproliferative signaling
mediated by this domain
SON shows an abnormal cytoplasmic localization
in t(8;21) cells; the functions are largely unknown
but it seems to be involved in regulation of
proliferation and apoptosis
Histone
deacetylases
[73]
Acetylation of
histones
Direct recruitment of HDACs with silencing of
AML1-target hematopoietic genes
There is physical binding between the fusion
protein and HDAC1, the ﬁnal functional eﬀect
being regarded as a leukemia-enhancing eﬀect
DNA methyl-
transferase 1 [76]
DNA
methylation
Silencing of gene expression through methylation,
probably functionally linked to HDACs
Contributes to the silencing of gene expression,
a n di si n v o l v e di nt h er e d u c e dI L 3e x p r e s s i o n
Protein kinase A
(PKA) [78]
Protein
phosphorylation
Binding to the NHR-3 domain of the fusion
protein
Even though PKA is important for regulation
of cell proliferation, the interaction with AML1-
ETO does not seem to have any major impact on
proliferation or in vivo leukemogenesis
Modulation of the fusion molecule
Calpains
[77]
Proteolytic
cleavage
Calpain is required for the induction of blood
disorders by the fusion protein in Drosophilia
Calpains cleave a restricted set of protein sub-
strates; one hypothesis is that the enzyme cleaves
the fusion protein, and thereby generates a more
potent inducer ofleukemiasimilarto theleukemic
splice variant. Alternatively calpains may aﬀect
leukemic cell migration
Alternative AML1/ETO splicing [62] One of the splice variants lacks the two
carboxyterminal ETO domains
In contrast to the full-length variant this alterna-
tively spliced molecule alone can induce leukemic
transformation in experimental models without
additional genetic abnormalities
3.4. The Fusion Protein Aﬀects a Wide Range of Biological
Functions. The fusion molecule aﬀects a wide range of
cellular molecules, and the data summarized in Table 4
illustrates the complexity of the AML1/ETO eﬀects [20, 62,
74, 76, 82–103]. Firstly, gene expression as well as ribosomal
function are aﬀected.Secondly,thefusionproteincanreduce
DNArepair [20]; this is combined with decreased expression
of the p53 tumor suppressor, and the ﬁnal eﬀect is probably
an increased risk of new leukemogenicevents[104]. A recent
study in Drosophila described that the fusion molecule
induced increased levels of reactive oxygen species (ROS);
these high ROS levels are important for the development8 Journal of Biomedicine and Biotechnology
of the AML1-ETO associated phenotype and may also
contribute to leukemogenesis through an increased risk of
developing additional genetic abnormalities [105]. Thirdly,
the responses to hematopoietic growth factors are altered;
this is due to altered cytokine release, receptor expression,
and probably also downstream intracellular signaling. These
events, together with altered cell-cycle regulation, will alter
the proliferative capacity of the cells. Finally, the regulation
of apoptosis is altered, and the cells show activation of stress
responses. Most of these alterations are in favor of increased
proliferation and survival and decreased diﬀerentiation
(Tables 3 and 4), but the fusion protein also has opposite
eﬀects, and this may explain why the fusion protein alone
cannot induce leukemic transformation (see above).
Two studies have shown that the fusion protein upreg-
ulates Connexin 43 (Cx43) (Table 4). Cx43 forms gap
junctionsandistherebyinvolvedincommunicationbetween
cells;ithasarolebothinnormalandleukemichematopoiesis
and may also function as an intracellular signaling molecule
independent of its role in gap junction formation [106,
107]. Thus, the eﬀect on Cx43 may represent an additional
leukemogenic mechanism in t(8;21) AML.
The fusion protein seems to preferentially bind those
AML1 target genes with duplicated binding sites in the
regulatory elements,and thisselectivity may beanimportant
mechanism for dysregulated gene expression and leukemo-
genesis [108]. Another selective regulatory mechanism is
possibly the epigenetic structure at the fusion protein’s target
sites; a recent study described that the most downregulated
genes were characterized by aberrant repressive histone
t a i lc h a n g e sb o t ha tt h eA M L 1c o n s e n s u sa sw e l la st h e
transcription start site [109].
Intracellular signaling is altered in t(8;21) AML. WT1-
mediated signaling may contribute to leukemogenesis, and
these patients seem to have increased WT1 levels [110].
Proteomic studies suggest that the t(8;21) abnormality also
interacts with the p53 network [111]. The survival and
growth of t(8;21) AML cells depend on autocrine loops
between vascular endothelial growth factor (VEGF) and
its receptors (VEGFR) that activate various downstream
pathways like PI-3 kinase, Akt, or MEK cascades [112,
113]. Both VEGFR1 and VEGFR2 monoclonal antibodies
suppressed the growth of primary AML cells with t(8;21),
an eﬀect mainly mediated through reduced phosphorylation
of Akt and MEK [114]. In addition, inhibition of VEGFR2
potentiated the growth inhibitory eﬀect of idarubicin for
the t(8;21) Kasumi-1 cell line though the mechanisms of
this eﬀect are not fully elucidated yet [114]. Another study
suggeststhatVEGFreceptortype-2-mediatedsignaling stim-
ulates proliferation of t(8;21) AML cells, an eﬀect mediated
through increased phosphorylation of Akt, and inhibition
of this signaling seems to potentiate the eﬀect of cytarabine
[115].
The global gene expression proﬁles of U937 AML cells
when expressing diﬀerent AML-associated fusion proteins
were compared in a recent study [116]. The analysis revealed
a role of AML1-ETO in downstream pathways known to
regulate DNA repair and stem-cell maintenance, including
activation of the Notch signaling pathway through Jagged-1
ligand [116, 117]. On the other hand, the eﬀect of AML1-
ETO depletion has been investigated by electroporating the
t(8;21)carrying Kasumi-1celllinewithspeciﬁcsiRNA[118].
This depletion severely diminished the cell clonogenicity,
inhibited G1-S transition, reduced apoptosis and induced
senescence. The presence of exogenous G-CSF or GM-CSF
could not rescue these cells from senescence but partly
counteracted the antiproliferative eﬀect.
The eﬀects of AML1-ETO on leukemic stem-cells have
not been investigated in detail. However, the eﬀect of AML1
alone on normal hematopoietic stem-cell homeostasis was
investigated in a recent study [119], and an enrichment of
quiescent stem-cells was observed in AML1-deﬁcient bone
marrow. These results suggest a negative regulatory eﬀect of
AML1 on normal stem-cells. Thus, the AML1-ETO fusion
molecule may then have an opposite eﬀect of AML1 on
leukemic stem-cells and cause an enrichment of quiescent
AML stem-cells similar to the AML1 deﬁciency through its
suppression of AML1 target genes (see Section 3.1).
4.AlternativeMethodsforDetectionof
t(8;21) inHumanAML
Cytogenetic analysis by G-banding is highly recommended
at the time of diagnosis of all AML patients [120]. Although
this time-consuming method requires the leukemic cells to
be captured in mitosis, it is still the best screening method
for detection of leukemia-speciﬁc chromosomal aberrations.
t(8;21) is readily detectable by G-banding (Figure 2), but
it can also occur due to variant rearrangements (complex
translocations, inversion, and insertion) that may be over-
looked if additional fusion-speciﬁc analyses like ﬂuorescence
in situ hybridization (FISH) or reverse transcriptase poly-
m e r a s ec h a i nr e a c t i o n( R T - P C R )a r en o tu s e d( Figure 2)
[121, 122]. Detection of the fusion protein is less common;
the protein can then be detected by Western blotting, but
a recently described method using immunobeads for ﬂow
cytometric detection seems promising and may represent a
future alternative [123].
FISH analysis for AML1-ETO fusion should be per-
formed using locus-speciﬁc probes. The advantage with this
method is that there is no need for cells in metaphase, and
it can, therefore, be performed also in bone marrow biopsies
or bone marrow/blood smears. Commercially available dual
color probes against AML1 and ETO resulting in fusion-
signals are most commonly used (Figure 2). Particular care
has tobetakenwhen interpreting thesignaling patterns from
interphase analyses, and dual-color double-fusion probes
should be used in order to reduce the false-positive rate.
A l t h o u g hr a r e ,o n eh a st ob ea w a r et h a tv a r i a n tA M L 1 - E T O
rearrangements can give only one fusion signal (Figure 2).
Probes covering the whole AML1 gene will also detect other
AML1 rearrangements, and instead of fusion signals, the
AML1 rearrangements will then be seen as two weaker
signals thatcan bemisinterpreted astrisomy 21in interphase
analyses. The chromosomal band 21q22 where the AML1
gene is situated, has been reported involved in 55 diﬀerent
rearrangements, and several of these can be overlooked by
G-banding, and the majority of these abnormalities haveJournal of Biomedicine and Biotechnology 9
Table 4: Important molecular mechanisms involved in AML1/ETO-induced leukemic transformation.
Molecule Function Eﬀect of AML1/ETO on the molecule Final eﬀect on t(8;21) cells
Altered gene transcription
PU.1 [82] Transcription factor Decreased expression by AML1/ETO Inhibition of diﬀerentiation
C/EBPα [83, 84] Transcription factor
Downregulation of C/EBPα;t h e
normal function of this factor is
regulation of diﬀerentiation and
inhibition of proliferation
Increased proliferation and inhibition of diﬀeren-
tiation
C/EBP β [85] Transcription factor The normal function is transcriptional
upregulation of C/EBPα
Altered regulation of diﬀerentiation and prolifera-
tion through reduced expression of C/EBPα
POU4F1 [86] Transcription factor
The POU4F1 levels are signiﬁcantly
correlated with the fusion protein
levels. One study described diﬀerential
regulation of 140 genes by this factor,
and half of them are also AML1/ETO
targets
POU4F1 probably contribute to the gene expres-
sion signature associated with t(8;21) AML
PAX5 [87, 88] Transcription factor Increased expression at the mRNA and
protein level
Aberrant expression of B lymphocyte markers,
including CD19, CD79a
RNA-rependent mechanisms and ribosomalfunctions
μRNA [62, 89] Regulatory RNA
molecules
The fusion protein selects a set of
μRNAs (miR); it occupies the
miR-24-23-27 locus and upregulates
their expression
Modulation of proliferation and diﬀerentiation
through the eﬀects on miR24 miR24 downregulates the
mitogen-activated protein kinase
phosphatase 7 and enhances the
downstream signalingthrough
phosphorylation of c-jun and p38
kinases
Silencing of miR223 through
epigenetic mechanisms
Altered regulation of myelopoiesis through eﬀects
on mir223
RNA polymerase I
[74]
Transcriptional
regulators
The fusion protein seems to localize to
the nucleolar organizing regions
during mitosis,associates with
metaphase chromosomes and occupies
ribosomal DNA repeats during
interphase together with UBF1 (see
Table 3)
In contrast to AML1 the fusion protein seems
to be a positive regulator of rDNA transcription.
Transcription regulated by RNA polymerase 1
seems to increase the proliferation of transformed
cells (discussed in [74])
DNA damage and repair
OGG1[20]D N A r e p a i r
OGG1 is an important part of the
DNA base excision repair pathway, its
expression is downregulated by the
fusion protein
High OGG1 levels are associated with an adverse
prognosis; the downregulation may increase che-
mosensitivity
DNA damage [90] Carcinogen-DNA
adducts
Increased formationof aromatic
hydrocarbon-DNA adducts and
upregulation of the cytochrome P450
1A1 enzyme that metabolizes
polycyclic aromatic hydrocarbons
This eﬀect may contribute to an increased suscep-
tibility to additional genetic damage
Increased intracellular
ROS [105]
Altered signalling.
DNA damage?
AML1-ETO causes increased
intracellular levels of reactive oxygen
species (ROS) in Drosophila
ROS are important for induction of the AML1-
ETO associated phenotype and may also increase
the risk of additional genetic abnormalities
Increased mutation
frequency [91] Predisposition to leukemia progression Predisposed for additional genetic eﬀects that are
required for leukemogenesis
Cytokine-mediated growth regulation
IL3 [76] Hematopoietic
growth factor Decreased gene expression Decreased growth factor-dependent proliferation
M-CSF receptor [92]G r o w t h f a c t o r M-CSF is a growth-enhancing
hematopoietic growth factor
Increased cytokine-dependent AML cell prolifer-
ation10 Journal of Biomedicine and Biotechnology
Table 4: Continued.
Molecule Function Eﬀect of AML1/ETO on the molecule Final eﬀect on t(8;21) cells
G-CSF receptor [93]G r o w t h f a c t o r G-CSF is a growth-enhancing
hematopoietic growth factor
Increased cytokine-dependent AML cell prolifer-
ation
BCL2 [94] Antiapoptotic
signaling
Upregulation by the AML1-ETO
fusion protein Increased antiapoptotic signaling
C/EBPε [92, 93] Transcriptional
regulator
Induction of G-CSF receptor
expression; upregulation of the
myeloid-speciﬁc promoter for the
M-CSF receptor
Increased growth factor receptor expression and
thereby increased cytokine-dependent prolifera-
tion by t(8;21) cells
NF1 [95] Tumor suppressor
Decreased expression of the
Neuroﬁbromatosis1 (NF1) tumor
suppressor
Decreased protein levels are associated with
increased response of primary AML cells to GM-
CSF
Tyrosine receptor
kinase A [96]
Ap a r to ft h en e r v e
growth factor
receptor (NGF)
Upregulation of this growth factor
both at the mRNA and protein level
NGF is released by bone marrow stromal cells;
in addition, AML1-ETO expressing cells show
increased proliferation in response to growth
factors
Cell-cycle regulation
p21 [97] Negative cell-cycle
regulator
Increased mRNA and protein levels of
p21
p21 is a cell-cycle inhibitor, this eﬀect may con-
tribute to the absence of leukemogenesis in the
presence of t(8;21) alone
p27kip [98] Negative cell-cycle
regulator
Increased expression caused by either a
direct eﬀect of the fusion protein or by
Cx43
Cell-cycle inhibition
SSX21P [99] Cell-cycle regulation?
Low expression of this molecule is
associated with low expression of
CDC20; possibly causing attenuation
of the spindle checkpoint
Altered cell-cycle regulation, increased risk of
aneuploidy?
Disrupted spindle
checkpoint [100] Aneuploidy Disruption of the spindle checkpoint
during cell-cycle progression Increased risk of aneuploidy
Regulation of apoptosis and stress responses
Annexin A1 [101] Proapoptotic,
antiproliferative
Downregulated at the gene expression
level by the fusion protein
The molecule has proapoptotic and antiprolifera-
tive eﬀects; these functions are thus inhibited
Connexin 43 (Cx43)
[98, 102]
Gap junction
component
Increased expression of Connexin 43
in cells with t(8;21), possibly both a
direct and an indirect eﬀect mediated
via c-Jun
Cx43 often inhibitscell proliferationboth through
gap junction dependent and independent mech-
anisms; this eﬀect may contribute to the lack of
leukemogenesis by the full-length fusion protein
p53 [91] Tumor suppressor Activation of the p53 pathway
Possibly increased chemosensitivity and thereby
contribution to the good prognosis of these
patients
TXNIP [103] Part of stress
responses
Involved in reactive oxygen stress
responses, AML cells with t(8;21) have
increased protein levels of this
molecule. The mechanism is not
known
High levels inhibit the proliferation of myeloid
progenitor cells; this may contribute to the good
prognosis of these patients
been found in AML/MDS [124]. If only interphases are
available, for analyses, the methodological alternative is to
verifyAML1rearrangementsbyusing AML1dualcolorsplit-
signal probes (Figure 2(c)). Thus, due to the possibility of
other less common AML1 rearrangements, the detection of
t(8;21) may require a careful interpretation of additional
molecular analyses before a ﬁnal conclusion can be reached.
RT-PCR is a rapid and sensitive method for detection
of the fusion transcript. Although simple to perform, the
method is not without challenges. RNA is readily degraded,
and tests for RNA quality have to be performed [125].
RT-PCRs are capable to detect one leukemic cell in 105-
106 normal cells [126], and this demands precautions to
avoid cross-contamination leading to false positive results.
Furthermore, the presence of leukemia-speciﬁc fusion tran-
scripts has been detected in tissue from healthy donors
whenusing nestedPCR.SingleroundPCRshould,therefore,
be suﬃcient at diagnosis [127] .F a l s en e g a t i v er e s u l t sc a n
occur if the assay is not designed to detect all diﬀer-
ent known fusion and transcript variants. As described
above (Section 3.2), several AML1-ETO variants have been
described due to alternative promoters and splicing, andJournal of Biomedicine and Biotechnology 11
diﬀerent variants can occur in the same patient. However,
most variants include exon 3–5 in AML1 and exon 2–4 in
ETO [17]. These regions can thus be used for design of the
primers; the problem of false-negative results can thereby be
reduced, and standardized protocols for RT-PCR have now
been published [128–131]. RT-PCR should thus be regarded
as a rapid and sensitive methodology, and it can even be
used for simultaneous screening for several prognostically
important fusion transcripts [132].
5.The Biological andClinicalCharacteristicsof
Humant(8;21)AML
5.1. The Diagnostic Criteria for AML in Patients with t(8;21).
The general diagnostic criterium for AML is detection of at
least 20% blasts in the bone marrow. However, t(8;21) AML
shows morphological signs of neutrophil maturation. Rare
cases can, therefore, be seen with bone marrow blast counts
below 20%; according to the WHO classiﬁcation, such cases
should also be classiﬁed and treated as AML and not as
myelodysplastic syndrome [3].
5.2. Morphological and Immunophenotypic Characteristics of
t(8;21)AML. Themorphologyoftheleukemiccellshasbeen
described by Arber et al. [3], the most common features
being relatively large blasts with basophilic cytoplasm, often
numerous azurophilic granules and a perinuclear clearing.
Auer rods are common and may be detected in blasts or
immature neutrophils. The cells show maturing to promye-
locytes and myelocytes, and mature neutrophils, possibly
with morphological signs of dysplasia, are also present
in the marrow. Among the dysplastic signs are abnormal
nuclear segmentation (e.g., pseudo-Pelger-Huet anomaly)
and cytoplasmic staining abnormalities like pink staining
in mature neutrophils. Eosinophilic precursors are often
increased; basophils and/or mast cells are also increased
sometimes. The erythroid cells and megakaryocytes are
morphologically normal. The abnormal diﬀerentiation of
the leukemic cells may even cause a morphological picture
similar to chronic myeloproliferative neoplasias. Lee et al.
[133] described a patient with variant t(8;21) as a complex
t(8;10;21) (q22;q24;q22) abnormality; this patient presented
with morphological ﬁndings in blood and bone marrow
mimicking atypical chronic myeloid leukemia.
The blasts express myeloperoxidase and are typically
CD13+CD34+HLA-DR+ [134]. There are also immunophe-
notypic signs of granulocyte maturation with subpopula-
tions expressing CD15 or CD65, eventually as a part of
asynchronous maturation with concomitant expression of
CD34 [134, 135]. Aberrant expression of the lymphoid
markers CD19, PAX5, and eventually cytoplasmic CD79a
is common [87]. CD56 can also be expressed especially
for patients with KIT mutations [134, 135], whereas CD19
expression is uncommon for patients with this mutation
[136].
5.3. Extramedullary Manifestations of AML. Myeloid sar-
coma is a rare condition that can involve almost any site of
thebody,butespeciallylymphnodesandskin(forreferences,
see [137]). Other common sites are head and neck soft and
subcutaneous tissue and the orbits, whereas intrathoracic
manifestation is uncommon [138, 139]. Such tumors can
be the ﬁrst manifestation and precede the primary bone
marrow manifestation by several months, or it can represent
the ﬁrst manifestation of a relapse [137–141]. Myeloid
sarcoma has been reported in 15% of patients with t(8;21)
AML [27]. However, t(8;21) is a relatively rare cytogenetic
abnormality in myeloid sarcomas; a recent cytogenetic study
of 74 patients with such sarcomas reported that the t(8;21)
abnormality was detected only in 2%-3% of these cases
[137].Thesarcomas inpatientswitht(8;21)canbelocatedto
uncommon regions, including (i)intracerebral tumors[142]
or intraspinal sarcoma with spinal cord compression [143]
(ii) abdominal aﬀection either as ovarial inﬁltration with
ascites[144]orcompressionofnervesornerveplexuses(e.g.,
presacral tumors) with neurological symptoms [145]; (iii)
skeletal or heart muscle aﬀection [146]; or (iv) pulmonary
involvement with initial symptoms resembling nodular or
interstitial pneumonia [133, 139]. Even though these lesions
may give serious local symptoms at the time of diagnosis, at
least in children detection of granulocytic sarcoma in t(8;21)
AML doesnot seemto havea majorimpact onthe long-term
survival [147].
5.4. Myelomastocytosis and Myelomastocytic Leukemia. Sys-
temic mastocytosis and AML,includingthe t(8;21)variant of
AML, can show similarities. Firstly, activating KIT mutations
are common both in t(8;21) AML and in systemic mas-
tocytosis [1]. Secondly, systemic mastocytosis can occur in
combination with other hematological malignancies, usually
myeloid malignancies (AML, myelodysplastic syndrome or
chronic myeloproliferative neoplasms) and in the WHO
classiﬁcation, this is termed systemic mastocytosis with
associated hematological nonmast cell disease [1]. Thirdly,
even though the combination of mastocytosis and t(8;21)
AML seems rare [148], the t(8;21) AML variant can show
phenotypic similarities with mastocytosis and has increased
serum tryptase levels (see below). The KIT mutations are
detected both in AML and mast cells in those rare cases
when mastocytosis is associated with AML; this observation
demonstrate that both cell types then are derived from the
same clone [149–151].
Due to the low number of published cases, it is not
possible to give general guidelines about the treatment of the
myelomastocytic leukemia variants. The bone marrow mast
cells seem to become more prominent after intensive AML
therapy, but this may simply be due to mast cell chemoresis-
tance as evidenced by their persistence after chemotherapy.
Some patients have been treated with allogeneic stem-cell
transplantation, and the very limited experience with this
therapeutic strategy suggests that the type of conditioning
therapy may be important for eradication of both AML and
mast cells [149, 150].
A recent study investigated serum tryptase levels in AML
[152]. Increased levels were detected in nearly half of AML
patientsand were associated witht(8;21)andKITmutations.
The levels decreased after chemotherapy [150, 152], suggest-
ing that serum tryptase can be used as a marker of treatment12 Journal of Biomedicine and Biotechnology
response in these patients. Thus, altered tryptase levels
seem relatively common in t(8;21) AML, but morphological
myelomastocytosis is rare. One possible explanation for the
increased levels could be tryptase release by the AML cells as
an ectopic phenotypic characteristic. Alternatively, the levels
may reﬂect an activation/stimulation of tryptase release by
normal mast cells. The association with KIT mutations
suggests that AML cell release is most likely.
5.5. Diﬀerences between Core-Binding Factor AML with
t(8;21) and inv(16)/t(16;16). Even though t(8;21) and
inv(16)/t(16;16) are both regarded as core-binding factor
AMLs with good prognosis, the two forms show several
diﬀerences in their pretreatment features. This has been
reviewed in detail by Mr´ ozek and Bloomﬁeld [43]. Firstly,
t(8;21) AML is more frequent in African than white Ameri-
cans, it has lower white blood cell counts and lower percent-
ages of blasts in the bone marrow. Secondly, extramedullary
disease is less frequent in t(8;21), especially lymphadenopa-
thy, splenomegaly, gingival hypertrophy, and skin/mucosa
involvement. Thirdly, the frequency and patterns of sec-
ondary cytogenetic abnormalities diﬀer. A secondary chro-
mosomal abnormality is detected in 70% of patients with
t(8;21)butonlyinone-thirdofinv(16)patients.Asdescribed
above (Section 2.2), the most frequent secondary abnormal-
ities in t(8;21) is loss of sex chromosomes and deletion
of 9q, whereas in inv(16), the most common are +22, +8,
del7q,and +21. Formutations detected by molecular genetic
methods, both KIT and Ras mutations occur, but they are
more frequent in inv(16), than in t(8;21) leukemia [33].
These pretreatment diﬀerences suggest that the molecular
mechanisms in the leukemogenesis diﬀer between these two
groups.
Mr´ ozek and Bloomﬁeld [43] also discussed possible
prognostic diﬀerences between t(8;21) and inv(16)/t(16;16)
AML. Observations from several studies suggest that relapse
of t(8;21) is less responsive to salvage treatment, and these
patients, therefore, have a lower overall survival. This diﬀer-
ence may be caused by the additional genetic abnormalities;
the KITmutationsassociated with t(8;21)AML seem to have
adverse prognostic eﬀects whereas +22 in inv(16) has been
associated with lower relapse risk in some studies. Finally,
there is possibly also an inﬂuence of genetic factors/race on
the response to chemotherapy in t(8;21) patients.
6.Animal Modelsoft(8;21)AML
Several animal models of t(8;21) AML have been developed,
including transgenic and knock-in models, conditional
k n o c k - i n ,a sw e l la sc h i m e r i cm o d e l s[ 153]. The models are
important for our current understanding of the role of the
AML1-ETO fusion protein in leukemogenesis (for detailed
discussionandreferencessee[153]).AML1knock-outcauses
embryonic death due to bleeding complications, and knock-
in modelsoftheAML1-ETOfusion generesulted in a similar
embryonic phenotype, suggesting that repression of AML1-
regulated genes are important in the fusion model. Fur-
thermore, one of the transgenic models directed the fusion
gene into the stem-cell compartment and its expression
was then signiﬁcantly lower in lymphoid cells than in
myeloid progenitors. This observation underlines the asso-
ciation between AML1-ETO expression and myelopoiesis.
Furthermore, transgenic mice that express the AML1-ETO
fusion molecule speciﬁcally in myeloid cells appeared to
be healthy and developed AML only if they in addition
were exposed to a mutagen [154]. These observations are
consistent with the hypothesis that the AML1-ETO fusion
protein alone is not suﬃcient for development of AML;
additional abnormalities have to be present [154]. Similar
observations have been made in other conditional knock-in
models and models based on retroviral transduction to the
stem-cellcompartment;thefusionproteinaloneoftenresults
onlyinincreased proliferativecapacityandalteredregulation
of diﬀerentiation. In one of these abnormalities an increase
in immature eosinophils similar to the human t(8;21) AML
was observed (discussed in detail in [153]).
Other chimeric models based on retroviral transduction
have also been published (reviewed in [153]). Transfection
of the AML1-domain alone from the fusion protein had
no eﬀect on hematopoiesis, showing that the ETO-derived
part of the molecule is required for development of the
hematopoietic abnormalities. Furthermore, the AML1-ETO
molecule has also been transfected to mice with otherabnor-
malities, including (i) deﬁciency of the myelosuppressive
Interferon regulatory factor (IRF), (ii) mutations in receptor
tyrosine kinases such as TEL/PDGFβR and Flt3; and (iii)
downregulation of the p21 cell-cycle inhibitor. All these
combinations resulted in development of AML. Thus, the
additional abnormalities cooperated with AML1-ETO in
leukemogenesis.
7.The Global Gene ExpressionProﬁle,
microRNA (MIR) Expression,and
EpigenomicProﬁleinHumant(8;21) AML
Global gene expression proﬁling in AML has revealed that
major prognostic subgroups based on genetic markers are
recapitulated in large-scale gene expression patterns [4, 155,
156]. These global proﬁles have identiﬁed speciﬁc signatures
for patients with the t(8;21) abnormality [4, 155, 156], and
its prediction can be made with almost 100% speciﬁcity and
sensitivity [157]. There is an overlap between the expression
proﬁles for the t(8;21) and inv(16) abnormalities [119], but
approximately one third of the transcripts are speciﬁc for
the t(8;21)-associated proﬁle [119]. RUNX1T1/ETO itself
has been identiﬁed as the most discriminative gene for
the t(8;21) cluster [4, 155], but several other genes are
also frequently up- or downregulated. Of special interest is
probably the transcription factor POU4F1 that is important
for embryonic brain development but without any known
role in normal or leukemic hematopoiesis. This gene is fre-
quently upregulated in t(8;21) AML [156]; this upregulation
is probably not directly caused by the AML1/ETO fusion
protein [86] but the unique transcription proﬁle of t(8;21)
AML is probably largely attributed to POU4F1 [86]. Finally,
AML1-ETO downregulates genes involved in multiple DNA
repair pathways, a possible explanation for the increased
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[91, 104]. Based on the results summarized in Table 4 we
conclude that the t(8;21) fusion protein alters the expression
levels of a wide range of molecules, and thereby aﬀects the
regulation of several intracellular processes; this conclusion
isalso supported by the t(8;21)-associated microarray proﬁle
(e.g., altered transcriptional regulation and DNA repair).
L¨ uck and coworkers identiﬁed two distinct gene expres-
sion signatures among t(8;21) and inv(16) AML based on
the presence of KIT mutations [158]. The KIT mutated cases
were then characterized by deregulation of genes belonging
to the NFκB signaling pathway [159]. On the other hand,
Bullinger and coworkers classiﬁed t(8;21) and inv(16) AMLs
in favorable and unfavorable prognostic subsets based on
supervised analysis of gene expression, the two distinct
groups being characterized by altered expression of genes
involved in the MAP-kinase and the mTOR pathways,
respectively [160]. All these pathways are suggested to play
a role in leukemogenesis and are considered as potential
therapeutic targets [161, 162].
A major part of the published clinical studies do not
ﬁnd any signiﬁcant prognostic impact of KIT mutations
(Section 2.2). The observations from the studies of global
gene expression proﬁles described above and the diﬀerent
eﬀects on intracellular signaling pathways for KIT mutations
(the NFκBp a t h w a yi sa ﬀected) compared with chemosensi-
tivity (MAP kinase)/chemoresistance (mTOR) are consistent
with the hypothesis that KIT mutations do not have any
major prognostic impact. This may be true at least for
the chemotherapy regimen used in these German/Austrian
studies [158, 160]. A possible explanation for the diﬀerent
prognostic impact between various studies may be that
the prognostic impact depends on diﬀerences between the
chemotherapy regimen.
The global gene expression analyses have identiﬁed addi-
tionalgenesthan thosesummarized in Table 4,whosealt er ed
expression may be clinically relevant [4, 155, 156]. Firstly,
PRAME (preferentially expressed antigen of melanoma) is
upregulated, and this AML-associated antigen is now used
in vaccination trials and may also be a candidate marker
for detection of minimal residual disease (MRD) [163, 164].
Secondly, the structural membrane protein CAV1 is also
upregulated, and this molecule is possibly important for
chemosensitivity [165]. Among the down-regulated genes
are the cystein protease CTSW cathepsin W, the cancer-
associatedactin-bundling proteinLCP1(lymphocytecytoso-
lic protein 1), the actin-regulatory protein CAPG (capping
protein, gelsolin-like) and the semaphorin receptor PLXNB2
(plexin B2). These genes seem to be involved in cancer cell
migration/invasion,cancer-associated angiogenesisortumor
progression [166–169].
It has been demonstrated that patient-derived AML
cells express a speciﬁc signature of microRNA, a class of
small noncoding RNAs involved in regulation of protein
coding mRNA [170, 171]. Most microRNAs seem to be
downregulated in t(8;21)AML except the miR126/126∗ that
is upregulated [170]. miR126/126∗ can inhibit apoptosis,
increase cell viability, and enhance colony formation pos-
sibly by interacting with AML1-ETO itself [171]. Finally,
studies in the t(8;21) positive Kasumi-1 cell line suggest
that the microRNA signature seems to be diﬀerent in the
CD34+CD38− AML cell subset which is believed to harbor
a major part of leukemic stem-cells [172].
DNA methylation and histone modiﬁcations are impor-
tant epigenetic mechanisms of gene regulation [173]. These
mechanisms seem to play essential roles both independently
and cooperatively in malign transformation and progression
[173]. This is also true for AML, where diﬀerent cytogenetic
subgroups, including t(8;21), seem to be characterized by
distinct epigenetic modiﬁcations [174–176]. However, the
clusteringseems to be lesspronounced based onmethylation
data compared to gene expression data [174]. The t(8;21)
DNA methylation cluster harbors patients not having the
AML1-ETO fusion gene, even though they seem to have
a similar prognosis and also share other features with
t(8;21) patients [175]. Furthermore, human hematopoietic
stem-cells transduced with the AML1/ETO fusion gene
failed to reproduce the epigenetic signature [176], sup-
porting the theory that other mutations are needed to
create the fully malign phenotype [154]. In contrast to
data from methylation studies, modiﬁcation of histone H3
Lysine 9 methylation was recently demonstrated to show
only minor diﬀerences between diﬀerent cytogenetic groups
[177].
8.The Prognostic Impact of
t(8;21) inHumanAML
8.1. Patients Receiving Conventional Intensive Chemotherapy.
t(8;21) is usually associated with a relatively low risk of
relapse. A recent MRC report analyzed the survival data for
5876 AML patients (median age 44 years) including 421
patients with t(8;21) [7]. The long-term disease-free survival
for this subset was 61%, and a similar high survival has also
been observed in other studies [178, 179]. No diﬀerence in
overall survival was then observed when comparing patients
witht(8;21)aloneversuspatientswithadditionalcytogenetic
abnormalities the only possible exception being loss of
the Y chromosome that was associated with an improved
survival of borderline signiﬁcance in the MRC study. A
French study investigated elderly patients (median age 67
years) with CBF-AML, including 60 patients with t(8;21)
[27]. These patients received induction treatment with an
anthracycline combined with cytarabine; 80% of the patients
achieved complete remission after one induction cycle and
88% after two cycles. However, despite this high remission
rate, the median 5-year overall survival for these patients
was only 31%. A high white blood cell count (WBC) at
diagnosis, poor performance status, and del(9q) were all
associated with an adverse prognosis, whereas administra-
tionofintensive consolidationtreatment wasassociated with
better survival. High WBC is in general considered as an
adverse prognostic factor in t(8;21); this is mainly based
on clinical studies indicating an unfavorable outcome for
patients with high WBC alone [27] or high WBC plus a
high percentage of bone marrow blasts [180]. AML t(8;21)
with high WBC (usually deﬁned as >20×109/L) is often
considered to have a less favorable prognosis similar to
the intermediate prognostic group in clinical studies [181]14 Journal of Biomedicine and Biotechnology
(e.g., the HOVON 102 AML/SAKK 30/09 study; EudraCT
number 2009-011613-24). Finally, it should also be men-
tioned that the adverse prognostic impact of KIT mutations
that is observed in certain studies may be explained by
an association between KIT mutations and high peripheral
blood blast counts [37].
A recent study described an adverse prognostic impact of
high bone marrow cellularity in patients with t(8;21) [182].
The authors found that the bone marrow cellularity was
the single most important prognostic parameter in these
patients, and they classiﬁed their patients in three groups
with (i) neither leukocytosis nor increased bone marrow
cellularity (ii) only leukocytosis (cutoﬀ 9.1×109/L),and (iii)
patients with increased marrow cellularity with or without
leukocytosis. The survival after chemotherapy was lowest
(32% overall 5-years survival) for the last group. These
results strongly suggest that bone marrow cellularity should
be further evaluated as a possible prognostic parameter in
these patients.
t(8;21) is also regarded as a good prognostic marker in
pediatric AML. The complete remission rate close to 100%,
eventfreesurvivalexceeding69%andoverallsurvivalexceed-
ing 80% have recently been reported for children included in
the MRC-AML10, MRC-AML12 and AML-BFM 98 studies
and with no eﬀect of additional chromosomal abnormalities
on prognosis [183, 184]. Other pediatric protocols have
reported eventfree survival below 50% [15, 185, 186], and
the reasons for this discrepancy remain to be identiﬁed.
However, children with relapsed t(8;21) AML seem to have
ac h a n c et ob ec u r e db ys a l v a g et h e r a p y[ 183, 184].
8.2. Experiences with Allogeneic Stem-Cell Transplantation
in t(8;21) AML. Two large studies each including more
than 300 patients have investigated the outcome after
allogeneic stem-cell transplantation for AML patients with
inv(16) and t(8;21) [187, 188]. Kuwatsuka et al. described
no diﬀerence between patients in ﬁrst remission receiving
allogeneic and autologous stem-cell transplantation, and
a long-term disease-free survival of 15%–20% was seen
even for 85 patients undergoing allotransplantation not
in complete remission [187]. As for patients receiving
conventional therapy, additional cytogenetic abnormalities
did not have any prognostic impact for these patients either.
Similarly, Gorin et al. observed a comparable survival for
auto- and allotransplanted patients of approximately 60%,
and additional cytogenetic abnormalities had no signiﬁcant
prognostic impact, but high white blood cell counts had an
adverse impact [188].
The smaller study by Schlenk et al. showed no advantage
of allotransplantation compared with conventional inten-
sive chemotherapy [189], thus supporting the two studies
described above. In contrast, Shin et al. observed that
the survival for allotransplanted patients had improved
d u r i n gt h el a s ty e a r sa n dw a ss i g n i ﬁ c a n t l yb e t t e rt h a nf o r
patients receiving high-dose cytarabine in a retrospective
multicenter study based on distribution of questionnaires
to each participating center [190]. In our opinion, most
of the currently available data suggest that allogeneic stem-
cell transplantation usually should not be recommended
for t(8;21) patients in ﬁrst complete remission. However,
the presence of additional KIT mutations, high WBC
counts and secondary leukemia have been associated with
an adverse prognosis (see Sections 2.2, 2.3,a n d8.1),
suggesting that allotransplantation should be considered
even in ﬁrst complete remission for the younger subsets
of these patients at least when an optimal donor is avail-
able.
The possible prognostic impact of KIT mutations
in combination with t(8;21) was discussed in detail in
Section 2.2. This question has been addressed in several
clinical studies, and both adverse prognosis and no prog-
nostic impact have been observed [30–36, 38–40, 47]. It
was recently recommended that core-binding factor AML
with KIT mutations should be classiﬁed as intermediate with
regard to prognosis [191]. However, it is in our opinion,
diﬃcult to recommend allogeneic transplantation for these
patients with its risk of early transplant-related mortality as
long as the results are conﬂicting and several studies show no
prognostic impact of the KIT mutations after conventional
chemotherapy.
8.3. Disease-Stabilizing Therapy in t(8;21) AML. The com-
bination of all-trans retinoica c i d( A T R A )t o g e t h e rw i t h
valproic acid or another histone deacetylase inhibitor is now
tried for disease-stabilization in human AML [192, 193].
Most of the patients included in these studies have not
been suitable for intensive chemotherapy; many of them
h a dr e l a p s e dd i s e a s e ,a n do n l yas m a l lm i n o r i t yh a dt ( 8 ; 2 1 ) .
Experiments in the t(8;21) positive Kasumi-1 cell line have
demonstrated that the AML1/ETO fusion protein recruits
an HDAC-containing repressor complex to the promoters
of AML1 target genes [73]. Valproic acid and probably also
other HDAC inhibitors cause a dissociation of the fusion
moleculefrom theHDACs.Histone acetylation therebyleads
to transcriptional reactivation and increased proapoptotic
signaling [73, 101].
Only a few clinical studies have investigated the eﬀect
of ATRA in t(8;21) AML, and the results are conﬂicting.
Treatment with ATRA alone for 40 days induced complete
hematologicalremission inonepatient[194],whereas others
have reported that coexpression of the t(15;17), and the
t(8;21)encodedfusionproteins canbeassociated with ATRA
resistance [195].
9.Detectionof Minimal ResidualDisease
int(8;21) AML
9.1. Methodological Strategies for Detection of MRD.
Although detection of the AML1-ETO fusion transcripts
represent a favorable prognostic marker, up to 30% of
patients will experience a relapse of the disease [7, 178, 179].
MRD means remaining leukemia cells in a patient judged
to be in complete hematological remission according
to conventional morphological criteria. AML1-ETO-
transcripts can persist in patients with t(8;21) even after
stem-cell transplantation with GVHD and in long-time
CR [196–200] ,b u ta ni n c r e a s ei nt h ef u s i o nt r a n s c r i p t
expression seems to be predictive of relapse [201].Journal of Biomedicine and Biotechnology 15
RT-PCR isa sensitive approach which identiﬁesleukemic
cellsin105-106 normal cells.Byusing quantitativeRT-PCR it
is easy to follow the patient through the course of the disease
[202]. Leroy et al. assessed the prognostic value of real-time
quantitative PCR in 21 AML1-ETO patients treated by the
same protocol and who all achieved CR. Blood and bone
marrow were collected at diagnosis, at CR, after intensive
consolidation therapy and every 3–6 months thereafter; the
median followup time being 15 months. The relapse rate was
higher in patients with high pretreatment fusion transcript
expression, and the absence of recurrent disease correlated
with posttherapeutic absolute transcript levels below 10−3
compared to the Kasumi-1 cell line, or more than 3 log
decreaseoftranscriptlevelscomparedtothelevelsatthetime
of diagnosis [202].
In a study by Ommen et al. various chromosomal
aberrations appeared to have diﬀerent relapse kinetics and
therefore optimal sampling intervals might diﬀer; the best
MRD sampling interval for AML1-ETO seems to be every
fourth month [203]. However, clinical utility of monitoring
MRD with such high sensitivity is still under investigation
and standardization of sampling procedures, handling and
shipment ofsamples aswell as thePCRanalyses are required.
Standardization of the assays is also necessary to allow
comparison of results in diﬀerent studies and for setting a
threshold for AML1-ETO-transcript expression that deﬁnes
molecular relapse [120, 204].
Multiparameter ﬂow cytometry is less sensitive, but can
be applied in the evaluation of MRD in most AML-cases
and provides additional information about remaining cells
(reviewed in [204]). The method is rapid and detects the
presence of 10−4 leukemic cells, but it is not as speciﬁc as
PCR due to the possibility of phenotypic shifts in relapsed
disease. Tandem analysis with RT-PCR and ﬂow cytometry
canimproveMRDdetection[205].InterphaseFISHmayalso
have a potential as an adjunct analysis to cytomorphology,
cytogenetics, or multiparameter ﬂow cytometry in the
identiﬁcationofMRD,since strong agreement betweenthese
methods has been described in large cohorts [206–208].
9.2. Clinical Consequences of MRD Detection. Beneﬁt from
preemptive treatment has been shown in PML-RARA acute
promyelocytic leukemias [209, 210], but for other acute
myeloid leukemia variants, few investigators have taken
clinical action on detection of molecular relapse. For clinical
utility, it has been shown that kinetics of the AML1-ETO
declinecorrelate to relapse rate and outcome[202, 205, 211].
Monitoring the diﬀerent alternative splice variants of the
fusion transcript has also shown that persistence of the
exon9a variant is indicative for later relapse [131].
We previously described that the translocation can be
detected on Guthrie cards and may thus occur in utero
(Section 2.1), the fusion protein alone is not suﬃcient
for leukemogenesis (Section 6) and (iii) the translocation
can persist for years after allotransplantation without any
signs of leukemia relapse (Section 9.1). Taken together,
these observations further support the hypothesis that
detection of the fusion transcript is not suﬃcient for
evaluation of the relapse risk. One should rather use
serial determinations; the detection of increasing AML-ETO
transcript levels or eventually the kinetics of the increase
m a yb em o r er e l i a b l et oe v a l u a t et h er i s ko fa ni m m i n e n t
relapse.
10.ConcludingRemarks
The t(8;21) variant of human AML is a heterogeneous
subsetcharacterized byacommondisease-speciﬁc molecular
translocation. This variant is often referred to as core-
binding factor AML together with the inv(16)/t(16;16) vari-
ants, but these two cytogenetically identiﬁed AML subsets
show several biological and clinical diﬀerences. In contrast
to other AML patients the diagnosis of t(8;21) AML can be
made evenwhen less than 20% leukemicblasts are present in
t h eb o n em a r r o w .T h ed i s e a s ei sc h a r a c t e r i z e db y( i )e c t o p i c
expression of B-cell associated molecules; (ii) additional
genetic abnormalities are common; (iii) the leukemic cells
show speciﬁc global gene expression and microRNA proﬁles;
and (iv) usually there is a low risk of leukemia relapse
after high-dose cytarabine therapy. Despite the common
fundamental cytogenetic characteristics, it should always
be remembered that this speciﬁc cytogenetic abnormality
identiﬁes a heterogeneous subset of patients.
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